The Novo Nordisk history is full of firsts, in both diabetes care and biopharmaceuticals. In diabetes care, our firsts include:
the first hospital dedicated exclusively to diabetes care
the first long-acting insulin (NPH)
the first insulin analog products
the first purified insulin
the first insulin pen delivery system
the first meglitinide oral antidiabetic agent
the first delivery system with a memory, and the first combined blood glucose monitoring and insulin dosing system
the first insulin pen enhanced with a colorful design for children and teenagers
and the first insulin analog approved for pump therapy.
We are also proud of being the first company to develop pituitary growth hormone (p-hGH), the first to develop biosynthetic human growth hormone (b-hGH) using recombinant DNA (rDNA) technology, and the first to sponsor a controlled study of daily subcutaneous growth hormone injections (versus intramuscular injections given three times a week).
Headquartered in Denmark, Novo Nordisk is a global health care company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy, and hormone replacement therapy.
Stock info (NYSE quotes delayed by 15 minutes. Currency in USD)